Cleary, James M.;
Wolpin, Brian M.;
Dougan, Stephanie K.;
Raghavan, Srivatsan;
Singh, Harshabad;
Huffman, Brandon;
Sethi, Nilay S.;
Nowak, Jonathan A.;
Shapiro, Geoffrey I.;
Aguirre, Andrew J.;
D'Andrea, Alan D.
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma
Contributor:
Cleary, James M.;
Wolpin, Brian M.;
Dougan, Stephanie K.;
Raghavan, Srivatsan;
Singh, Harshabad;
Huffman, Brandon;
Sethi, Nilay S.;
Nowak, Jonathan A.;
Shapiro, Geoffrey I.;
Aguirre, Andrew J.;
D'Andrea, Alan D.
imprint:
American Association for Cancer Research (AACR), 2021
Description:
<jats:title>Abstract</jats:title>
<jats:p>Pancreatic cancer is rapidly progressive and notoriously difficult to treat with cytotoxic chemotherapy and targeted agents. Recent demonstration of the efficacy of maintenance PARP inhibition in germline BRCA mutated pancreatic cancer has raised hopes that increased understanding of the DNA damage response pathway will lead to new therapies in both homologous recombination (HR) repair-deficient and proficient pancreatic cancer. Here, we review the potential mechanisms of exploiting HR deficiency, replicative stress, and DNA damage-mediated immune activation through targeted inhibition of DNA repair regulatory proteins.</jats:p>